FDA OK's Boehringer/Lilly type 2 diabetes drug Jardiance
This article was originally published in Scrip
Executive Summary
After initially being snubbed by the FDA, Boehringer Ingelheim's and Lilly's sodium glucose co-transporter 2 (SGLT2) inhibitor Jardiance (empagliflozin) gained the agency's blessing on 1 August as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.